Heart failure (HF) is a rapidly growing public health issue with an estimated prevalence of >37.7 million individuals globally. HF is a shared chronic phase of cardiac functional impairment secondary to many aetiologies, and patients with HF experience a range of symptoms that affect their quality of life, including dyspnoea, fatigue, poor exercise tolerance and fluid retention.

The burden of HF will continue to rise, due to population aging, population growth and improved treatment of HF and other cardiovascular disorders. As a result, clinicians will be increasingly challenged to develop treatment plans and care systems that reduce the high levels of morbidity and mortality experienced by these patients, both from their HF and other comorbidities.


Sodium–glucose Cotransporter 2 Inhibitors in Heart Failure


30 April 2019


European Cardiology Review 2019;14(1):23-32

A PRMT5 Selective Inhibitor EPZ015666 Suppressed TAC-induced Left Ventricular Dysfunction


European Cardiology Review 2018;13(2):130.

Relationship Between VEGF-C Levels and All-cause Mortality in Patients with Chronic Heart Failure


European Cardiology Review 2018;13(2):129.

The Mechanism of Hey2 Expression in Cardiac Development


European Cardiology Review 2018;13(2):128.